On or around 10/25/2017 (Stipulation and order of dismissal (voluntary dismissal))
Filing Date: July 24, 2015
According to the law firm press release, the complaint alleges that throughout the Class Period, defendants made false and/or misleading statements that Xoma Corporation's EYEGUARD-B clinical trial would succeed and/or surpass expectations across the study's primary endpoint. On July 22, 2015, defendants revealed that the Phase 3 EYEGUARD-B study had failed. On this news, the price of Xoma stock declined by $3.48 per share, or over 79%, on extremely heavy trading volume.
Plaintiffs filed an amended complaint on July 8, 2016.
On September 28, 2017, the Court issued an Order granting Defendants' Motion to Dismiss with leave to amend. Plaintiffs decided to voluntarily dismiss this action on October 24.
Company & Securities Information
Defendant: XOMA Corporation
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: XOMA
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Joseph F. Markette, et al. v. XOMA Corporation, et al.